Royal Bank Of Canada Issues Pessimistic Forecast for aTyr Pharma (NASDAQ:ATYR) Stock Price

aTyr Pharma (NASDAQ:ATYR) had its target price decreased by analysts at Royal Bank Of Canada to $6.00 in a report issued on Friday, Benzinga reports. The firm currently has a “sector perform” rating on the stock. Royal Bank Of Canada‘s price target would suggest a potential downside of 5.88% from the company’s previous close.

Other analysts have also recently issued research reports about the stock. Weiss Ratings cut aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, September 16th. Wall Street Zen upgraded aTyr Pharma to a “hold” rating in a research note on Saturday, October 31st. Finally, Wells Fargo & Company upped their price objective on aTyr Pharma from $1.00 to $4.00 and gave the stock an “equal weight” rating in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, aTyr Pharma currently has an average rating of “Hold” and an average target price of $5.00.

aTyr Pharma Stock Up 5.7%

Shares of aTyr Pharma stock traded up $0.35 during trading on Friday, reaching $6.38. The company’s stock had a trading volume of 39,828 shares, compared to its average volume of 65,991. The business’s 50-day moving average price is $11.99 and its 200-day moving average price is $23.70. The firm has a market cap of $15.63 million, a PE ratio of -0.26 and a beta of 1.04. aTyr Pharma has a 52 week low of $4.07 and a 52 week high of $44.40.

aTyr Pharma (NASDAQ:ATYR) last announced its quarterly earnings results on Friday, November 6th. The company reported ($7.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($4.00) by ($3.43). Equities analysts predict that aTyr Pharma will post -17.80 earnings per share for the current year.

Institutional Investors Weigh In On aTyr Pharma

An institutional investor recently raised its position in aTyr Pharma stock. Bank of America Corp DE boosted its holdings in aTyr Pharma, Inc. (NASDAQ:ATYR) by 139.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 303,559 shares of the company’s stock after acquiring an additional 176,859 shares during the quarter. Bank of America Corp DE owned about 0.31% of aTyr Pharma worth $237,000 as of its most recent SEC filing. Institutional investors own 61.72% of the company’s stock.

About aTyr Pharma

aTyr Pharma, Inc (NASDAQ:ATYR) is a biotechnology company focused on developing therapies that modulate immune system activity. The company’s research is based on a class of naturally occurring proteins known as extracellular tRNA synthetases, which can influence biological processes involved in inflammation, tissue repair and immune regulation.

aTyr’s lead product candidate is efzofitimod, an engineered protein therapeutic designed to target neuropilin-2 and regulate immune responses in the lungs.